Penwest Pharmaceuticals (PPCO) Announces Results of Phase Ib Trial of A0001

July 16, 2009 8:40 AM EDT

Penwest Pharmaceuticals Co. (Nasdaq: PPCO) announced the results of its Phase Ib clinical trial of A0001, a compound the Company is developing for the treatment of mitochondrial diseases. Drs. Amale Hawi, Senior Vice President, Pharmaceutical Development, and Thomas Sciascia, Senior Vice President & Chief Medical Officer, will be presenting these results at the Friedreich's Ataxia Therapeutics Meeting on Friday, July 17, 2009, in Philadelphia, PA.

In the Phase Ib trial, the drug was well tolerated by subjects, and no serious adverse events were reported. There was a dose-dependent increase in exposure approaching steady state within 2-4 days following repeat-dosing, and a maximum tolerated dose was established.

Subscribe to EasyStockAlerts.com & Get real-time e-mail alerts when news hits your stocks!
Penwest is a drug development company focused on identifying and developing products that address unmet medical needs, primarily for rare disorders of the nervous system.

Create E-mail AlertRelated Categories

Corporate News
FDA

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?